Figure 1From: Dual color chromogenic in situ hybridization for determination of HER2 status in breast cancer: a large comparative study to current state of the art fluorescence in situ hybridization Images of specimens stained with HER2 CISH pharmDx™ Kit. Images representing a HER2 gene amplified (HER2/CEN-17 ratio 2.0) specimen to the left and a non-amplified specimen (HER2/CEN-17 ratio < 2.0) to the rightBack to article page